4-phenylpiperdine-pyrazole CCR1 antagonists

Details 4-phenylpiperdine-pyrazole CCR1 antagonists 4-phenylpiperdine-pyrazole CCR1 antagonists

2006-10-11

2009-08-18

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S326000

Reexamination Certificate

active

07576218

ABSTRACT:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

REFERENCES:
patent: 4853384 (1989-08-01), Helsley et al.
patent: 6043257 (2000-03-01), Dominguez et al.
patent: 2004/0014783 (2004-01-01), Rigby et al.
patent: 2004/0259914 (2004-12-01), Ko et al.
patent: 2005/0070609 (2005-03-01), Finke et al.
patent: 2005/0143372 (2005-06-01), Ghosh et al.
patent: 2007/0093467 (2007-04-01), Zhang et al.
patent: 2001019672 (2001-01-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 01090101 (2001-08-01), None
patent: WO 03/000688 (2003-01-01), None
patent: WO 03/013526 (2003-02-01), None
patent: WO 03037274 (2003-02-01), None
patent: WO03105853 (2003-11-01), None
patent: WO 2004/009550 (2004-01-01), None
patent: WO 2004054974 (2004-07-01), None
patent: WO 2006/066948 (2006-06-01), None
Xie, et. al. “Identification of novel series of human CCR1 antagonists,” Bioorganic & Medicinal Chemistry Letters 2007, doi: 10.1016/j.bmcl.2007.09.068.
Brown et. al. “Novel CCR1 antagonists with improved metabolic stability” Bioorganic & Medicinal Chemistry Letters 2004, 14, 2175-2179.
De Lucca et. al. “Discovery and Structure-Activity Relationship of N-(Ureidoalkyl)-Benzyl-Piperidines As Potent Small Molecule CC Chemokine Receptor-3 (CCR3) Antagonists” J. Med. Chem. 2002, 45, 3794-3804.
Ng et. al. “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists” J. Med. Chem. 1999, 42, 4680-4694.
International Search Report mailed on Sep. 27, 2007, for PCT Application No. PCT/US06/40014 filed on Oct. 11, 2006, two pages.
Dominguez et al., “Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.” Bioorganic & Medicinal Chemistry Letters, 1999, 9, pp. 925-930.
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor.”J. Biol. Chem., vol. 273, No. 25, pp. 15687-15692, 1998.
Liang et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1.”J. Biol. Chem., vol. 275, No. 25, pp. 19000-19008, 2000.
Liang et al., “Species Selectivity of a Small Molecule Antagonist for the CCR1 Chemokine Receptor.”Eur. J. Pharmacol., vol. 389, No. 1, pp. 41-49, 2000.
Ng et al., “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists.”J. Med. Chem., vol. 42, No. 22, pp. 4680-4694, 1999.

Affiliated with

Also associated with

Rating

4-phenylpiperdine-pyrazole CCR1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-phenylpiperdine-pyrazole CCR1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-phenylpiperdine-pyrazole CCR1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4060219